This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Angiotensin receptor neprilysin inhibitors (ARNI) evidence in heart failure with preserved ejection fraction (HFpEF) Cochrane review 2021

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (HFpEF)

  • a Cochrane review (41 RCTs, n=23,492) found moderate certainty evidence that mineralocorticoid receptor antagonists (MRA) and angiotensin receptor neprilysin inhibitors (ARNI) may reduce heart failure hospitalisation, but probably have little or no effect on cardiovascular mortality and quality of life

    • evidence that MRA and ARNI treatment in HFpEF probably reduces heart failure hospitalisation but probably has little or no effect on cardiovascular mortality and quality of life

    • BB (beta blockers) treatment may reduce the risk of cardiovascular mortality, however, further trials are needed

    • current evidence for BBs, ACEIs (ACE inhibitors), and ARBs (angiotensin recetptor blockers) is limited and does not support their use in HFpEF in the absence of an alternative indication

    • although MRAs and ARNIs are probably effective at reducing the risk of heart failure hospitalisation, the treatment effect sizes are modest

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.